Table 1.

Summary of cases with PTTM treated with imatinib

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6 (our case)
Age at onset, y	47	61	64	61	45	56
Sex	F	M	F	F	F	F
Author	Ogawa A	Higo K	Minatsuki S	Fukuda I	Fukuda I	Kubota K
Year of report	2013	2014	2015	2015	2016	2017
Primary disease	Gastric adenocarcinoma (signet-ring cells)	Colorectal cancer	Gastric adenocarcinoma (signet-ring cells)	Breast cancer	Breast cancer	Gastric adenocarcinoma (signet-ring cells)
Drugs administered	Imatinib 100 mg bosentan 93.75 mg epoprostenol 27 ng/kg/min	Imatinib 50→200 mg bosentan tadalafil	Imatinib 200 mg sildenafil 60 mg ambrisentan 10 mg	Imatinib 200→400 mg tadalafil 40 mg	Imatinib 200→400 mg	Imatinib 200 mg bosentan 62.5 mg tadalafil 40 mg
Mean PAP after administration of imatinib	47→25 mm Hg	48→35 mm Hg	48→33 mm Hg	60→56 mm Hg	27→30 mm Hg	47→22 mm Hg
Chemotherapy	TS-1 40 mg	Bevacizumab 5 mg/kg TS-1 100 mg	TS-1	Eribulin	Capecitabine	TS-1 oxaliplatin
Surgical therapy	(–)	(–)	Total gastrectomy	(–)	(–)	(–)
Survival time	9 months	12 months	12 months	54 days	24 days	7 months
Cause of death	Metastasis	Infection	Metastasis	Respiratory failure	Respiratory failure	Metastasis

PAP, pulmonary arterial pressure; PTTM, pulmonary tumour thrombotic microangiopathy; TS, titanium silicate.